The fight against cancer is continuously being advanced by new targeted therapies, and the synthesis of these complex molecules relies on sophisticated chemical building blocks. Among these, tert-Butyl 4-Bromo-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzoate (CAS: 1628047-84-6) stands out as a critical intermediate. Its primary application lies in the development of apoptosis-inducing agents, specifically as a precursor for the potent BCL-2 inhibitor, Venetoclax (ABT-199). Understanding the chemical nature and utility of this compound is vital for researchers and procurement managers in the pharmaceutical sector.

Chemical Profile and Significance

Tert-Butyl 4-Bromo-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzoate possesses a molecular formula of C18H17BrN2O3 and a molecular weight of approximately 389.24 g/mol. Its physical appearance is typically a white powder, with high purity standards often exceeding 98.0%. This level of purity is non-negotiable for pharmaceutical applications, ensuring that downstream reactions proceed efficiently and the final active pharmaceutical ingredient (API) meets stringent quality benchmarks. The presence of the bromo substituent and the tert-butyl ester group provides specific reaction handles that are essential for constructing the intricate structure of Venetoclax.

From Intermediate to Therapeutic Agent

Venetoclax (ABT-199) is a groundbreaking drug that selectively inhibits the BCL-2 protein, a key regulator of apoptosis (programmed cell death). By targeting BCL-2, Venetoclax effectively triggers the self-destruction of cancer cells, particularly in certain types of leukemia and lymphoma. The synthesis pathway of Venetoclax involves several complex steps, with tert-Butyl 4-Bromo-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzoate serving as a fundamental building block. Sourcing this intermediate from a reliable manufacturer ensures that the complex supply chain for such advanced therapies remains robust.

Procurement Considerations for Research and Manufacturing

For companies involved in pharmaceutical R&D or commercial manufacturing, procuring tert-Butyl 4-Bromo-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzoate requires careful consideration. Key factors include supplier reputation, purity specifications, batch-to-batch consistency, lead times, and pricing. Engaging with experienced chemical manufacturers and suppliers, particularly those located in China known for their advanced chemical synthesis capabilities, can provide access to high-quality materials at competitive prices. Requesting detailed product information and samples is a critical step before committing to a bulk purchase.

Conclusion

Tert-Butyl 4-Bromo-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzoate (CAS 1628047-84-6) is more than just a chemical compound; it is an enabling component for cutting-edge cancer therapies. Its role as a vital intermediate in Venetoclax synthesis underscores the importance of precise chemical manufacturing and reliable global sourcing networks. For anyone in the pharmaceutical industry seeking this critical precursor, understanding its chemical properties and the procurement process is key to advancing therapeutic innovation.